$13.99
Today
as of Jul 22, 16:47 ET
Last 30 days
Recent Press Releases & News
Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy?
Corvus Pharmaceuticals Faces Key Soquelitinib Data And Possible M&A Interest
Is Corvus Pharmaceuticals, Inc. (CRVS) A Good Stock To Buy Now?
Overview
52-week range
$3.55
$27
45% of range
Avg surprise (last 3)
+5.3%
Avg reaction (last 2)
-0.4%
50% positive
Latest IV / EM
87%
EM ±19.8% · $14 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-0.15 | $-0.14 | -7.1% | -15.4% | -5.6% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.12 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-0.10 | $-0.13 | +23.1% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.13 | $-0.13 | 0.0% | — | +4.7% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.60 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.07 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.12 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.12 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.14 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 6, 2026 | Jun/2026 | OTHER | -$0.17 | -$0.10 | -70.0% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-15M | — | $-11M | $-10M | $-10M | — | $-7M | $-6M |
| Net income | $-14M | — | $-10M | $-8M | $15M | — | $-40M | $-4M |
| EPS (diluted) | $-0.15 | — | $-0.12 | $-0.10 | $-0.13 | — | $-0.60 | $-0.07 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $40M | $5M | $3M | $15M | $5M | $9M | $5M | $15M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $240M | $58M | $67M | $76M | $45M | $54M | $43M | $48M |
| Total assets | $253M | $71M | $80M | $89M | $59M | $69M | $59M | $65M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $13M | $10M | $9M | $9M | $10M | $36M | $46M | $13M |
| Total equity | $241M | $61M | $72M | $80M | $49M | $33M | $12M | $51M |